Modified-Release Oral Contraceptive Composition for Low-Estrogen Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing combined oral contraceptives (COCs) with low estrogen doses face challenges in maintaining effective contraceptive efficacy, tolerability, and acceptable bleeding patterns, leading to compliance issues and increased pregnancy risk.
Innovation Solution
A prolonged-release oral contraceptive composition comprising 2 mg of dienogest and equal to or less than 0.02 mg of ethinyl estradiol, with at least 80% of the ethinyl estradiol intended for slow release, providing a reliable contraceptive effect and improved bleeding patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the dose of ethinyl estradiol is reduced to lower VTE risk and adverse events, then safety is improved, but contraceptive efficacy and cycle control deteriorate
Solution Approach 1:
The patent segments the release of ethinyl estradiol into two distinct phases: an initial rapid release phase providing immediate hormonal effect, and a subsequent slow release phase maintaining stable levels. This segmentation allows the low-dose formulation to achieve both safety (through reduced total dose) and efficacy (through optimized release kinetics) that a single-dose regimen cannot provide.
Solution Approach 2:
The invention introduces dynamic release characteristics for ethinyl estradiol, transitioning from static immediate-release or uniform slow-release formulations. The dual-phase release pattern dynamically adapts hormone delivery to match physiological needs, with rapid initial release for onset of action and controlled slow release for sustained effect, thereby maintaining contraceptive efficacy at lower doses.
2Object-affected harmful factors
If the dose of ethinyl estradiol is reduced to improve tolerability, then adverse events decrease, but bleeding patterns deteriorate
Solution Approach 1:
By segmenting ethinyl estradiol release into rapid and slow phases, the formulation achieves stable bleeding patterns through controlled hormone delivery. The rapid phase ensures sufficient initial hormone levels to prevent breakthrough bleeding, while the slow phase maintains steady-state levels to regulate the endometrium, thereby improving tolerability without compromising cycle control.
Solution Approach 2:
The invention changes the release rate parameter of ethinyl estradiol from immediate or uniform release to a dual-phase pattern. This parameter change optimizes the balance between adverse event reduction and bleeding pattern stability, allowing lower total doses to achieve both improved tolerability and acceptable cycle control.
3Reliability
If conventional rapid release formulations are used, then contraceptive efficacy is achieved, but peak fluctuations increase leading to more adverse events
Solution Approach 1:
The patent segments ethinyl estradiol release into rapid and slow phases, where the rapid phase provides initial efficacy and the slow phase smooths peak fluctuations. This segmentation reduces the magnitude of Cmax while maintaining adequate hormone levels for contraceptive protection, thereby decreasing adverse events like breast tenderness and nausea compared to conventional immediate-release formulations.
Solution Approach 2:
The invention introduces dynamic release characteristics that adapt hormone delivery over time. The transition from static rapid-release to dynamic dual-phase release reduces peak-to-trough fluctuations, maintaining more stable serum hormone levels and thereby reducing concentration-dependent adverse events while preserving contraceptive efficacy.
Data Source
AI summary
The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) and 17α-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.